GRAIL, Inc. (GRAL)
NASDAQ: GRAL · Real-Time Price · USD
50.21
-51.32 (-50.55%)
At close: Feb 20, 2026, 4:00 PM EST
49.39
-0.82 (-1.63%)
After-hours: Feb 20, 2026, 7:59 PM EST
GRAIL Revenue
In the year 2025, GRAIL had annual revenue of $147.17M with 17.18% growth. GRAIL had revenue of $43.60M in the quarter ending December 31, 2025, with 13.97% growth.
Revenue (ttm)
$147.17M
Revenue Growth
+17.18%
P/S Ratio
13.76
Revenue / Employee
$147,172
Employees
1,000
Market Cap
2.03B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 147.17M | 21.58M | 17.18% |
| Dec 31, 2024 | 125.60M | 32.49M | 34.90% |
| Dec 31, 2023 | 93.11M | 37.56M | 67.61% |
| Jan 1, 2023 | 55.55M | 40.94M | 280.17% |
| Jan 2, 2022 | 14.61M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| RadNet | 1.97B |
| Sotera Health Company | 1.15B |
| Neogen | 880.32M |
| NeoGenomics | 727.33M |
| OPKO Health | 642.07M |
| Veracyte | 495.14M |
| GeneDx Holdings | 402.19M |
| Twist Bioscience | 391.56M |
GRAL News
- 1 day ago - This once-hot cancer-detection company's stock got cut in half after a failed trial - Market Watch
- 1 day ago - Grail shares plunge after major cancer screening trial misses main goal - Reuters
- 1 day ago - Grail Stock Plunges 50% After Earnings. But It's These Test Results That Are to Blame. - Barrons
- 1 day ago - Grail Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - Business Wire
- 1 day ago - GRAIL, Inc. (GRAL) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - GRAIL Reports Fourth Quarter and Full Year 2025 Financial Results - PRNewsWire
- 2 days ago - Landmark NHS-Galleri Trial Demonstrates a Substantial Reduction in Stage IV Cancer Diagnoses, Increased Stage I and II Detection of Deadly Cancers, and Four-Fold Higher Cancer Detection Rate - PRNewsWire
- 5 days ago - GRAIL to Announce Fourth Quarter and Full Year 2025 Financial Results - PRNewsWire